Lifeboat Foundation

Billionaire investor Jim Mellon has joined the push to solve age-related diseases and bring rejuvenation biotechnology to the world.

Billionaire biotechnology investor Jim Mellon has unveiled an investment in an ambitious new venture which seeks to tackle ageing and age-related diseases.

Insilico Medicine is a big data analytics company which says its mission is to ‘extend healthy longevity’.

Continue reading “Billionaire Jim Mellon invests in anti-ageing research firm” »

A new report from The Scripps Research Institute in California has found a way to make cells resistant to HIV. Antibodies bind to cell receptors that block the virus from infecting it.

https://www.youtube.com/watch?v=kEGccyXSQAU

New one from Liz.

Full Video ► https://goo.gl/tHvTF5
BioViva ► http://bioviva-science.com

Continue reading “Liz Parrish — Human of the Future” »

The ruling class tell us universal healthcare is ‘unfeasible’ while they pour millions into immortality drugs and seek godhood itself.

This week saw researchers announce a promising new approach to Parkinson’s by the use of cellular reprogramming. The team lead by Ernest Arenas used a cocktail of four transcription factors to reprogram support cells inside the brain.

The research team placed the reprogramming factors into a harmless type of lentivirus and injected them en masse into a Parkinson’s disease model mice. The viruses infected support cells in the brain known as astrocytes (a support cell that regulates the transmission of electrical impulses within the brain) which are present in large numbers. The lentiviruses delivered their four factor payload to the target cells changing them from astrocytes into dopamine producing neurons.

Within three weeks the first cells had been reprogrammed and could be detected, and after fifteen weeks there were abundant numbers of dopamine producing neurons present. This is good news indeed as it also confirms that once reprogrammed the cells remain changed and stable and do not revert back into astrocytes.

Continue reading “Reprogramming brain cells offers hope for Parkinson’s” »

Scientists develop a new method to regrow microscopic hair cells that pick up sound.

Interest in rejuvenation biotechnology is growing rapidly and attracting investors.

- Jim Mellon has made an investment in Insilico Medicine to enable the company to validate the many molecules discovered using deep learning and launch multi-modal biomarkers of human aging

Monday, April 10, 2017, Baltimore, MD — Insilico Medicine, Inc, a big data analytics company applying deep learning techniques to drug discovery, biomarker development, and aging research today announced that it has closed an investment from the billionaire biotechnology investor Jim Mellon. Proceeds will be used to perform pre-clinical validation of multiple lead molecules developed using Insilico Medicine’s drug discovery pipelines and to advance research in deep learned biomarkers of aging and disease.

Continue reading “Billionaire investor to accelerate research in artificial intelligence in healthcare” »

Everolimus heading for human clinical trials later this year to treat immune system decline.

The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis.

PureTech have recently announced a joint venture with Novartis called resTORbio and are moving to clinical trials of the new drugs later this year. The aim of the first test phase is to see if the new drug can rejuvenate the immune system of aged people a key reason why we lose the ability to resist diseases as we grow older.

Continue reading “New drug aimed at slowing aging heads to the clinic” »

For people in that area, and it may be worth while to try reaching out to them for funding for anti aging stuff.

Why is RAND opening a Bay Area office?

The San Francisco Bay Area is really at the center of technology and transformation. That’s also been a focus at RAND since our very first report, Preliminary Design of an Experimental World-Circling Spaceship, in 1946, which foretold the creation of satellites more than a decade before Sputnik.

Continue reading “Innovation in the Bay Area: Q&A with Nidhi Kalra” »